Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically detailing changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
On August 4, 2011, several directors and officers purchased Ordinary shares of GlaxoSmithKline plc at a price of 1,327 pence per share. These purchases resulted from the reinvestment of dividends on shares held within Individual Savings Accounts (ISAs). The specific changes in share interests are as follows:
- Mr A P Witty: 26 shares
- Mr S M Bicknell: 69 shares
- Mr E J Gray: 7 shares
- Mr D S Redfern: 7 shares
- Mrs V A Whyte: 14 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of director share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,327 pence per Ordinary share on August 4, 2011.
- Confirm the total number of shares acquired by each named director through dividend reinvestment.
- Review the company's broader financial reports for the period to assess overall performance, as this filing contains no financial data.